Allison Clemens
April
ababaabhay
achoi2392
adhoward1

2025 PACUPrep BCCCP Preparatory Course Mechanical Ventilation Pharmacotherapy Pharmacotherapy in Mechanical Ventilation

Lesson 6, Topic 5

In Progress

← Previous

Pharmacotherapy in Mechanical Ventilation

Lesson Progress

0% Complete

Monitoring Safety, Dose Optimization, and Liberation Pharmacotherapy

Objective

Monitor pharmacotherapy efficacy, adjust dosing, and optimize transitions of care in mechanically ventilated patients.

1. Introduction

As patients approach extubation, vigilant monitoring of drug-related adverse events, individualized dose adjustments, and structured transitions from IV to enteral regimens are essential to minimize complications and facilitate recovery.

Key Points:

Optimize sedation and analgesia to balance comfort with the ability to assess neurological status.
Anticipate and monitor for common adverse effects of sedatives, analgesics, and neuromuscular blockers.
Engage multidisciplinary teams early to plan medication reconciliation and weaning protocols.

2. Monitoring for Adverse Drug Events

Early detection of sedation- and analgesia-related complications prevents hemodynamic instability, arrhythmias, gastrointestinal dysfunction, and neuromuscular toxicity.

A. Hemodynamic Effects

Hypotension with propofol:

Mechanism: systemic vasodilation and negative inotropy
Monitoring: continuous blood pressure; adjust infusion rate by 5–10 mcg/kg/min increments
Prevention: volume optimization before initiation; consider alternative agent if refractory hypotension

Bradycardia with dexmedetomidine:

Mechanism: sympatholysis via α2-agonism
Monitoring: continuous heart rate and blood pressure
Management: omit loading dose in vulnerable patients; reduce infusion by 0.2 mcg/kg/hr if HR <50 bpm

Key Pearl: Hemodynamic Titration

Titrate sedatives slowly in patients with marginal hemodynamics to minimize abrupt cardiovascular changes.

B. Cardiac Conduction Abnormalities

QT prolongation:

Agents: haloperidol, ziprasidone
Risk factors: electrolyte abnormalities, underlying cardiac disease, polypharmacy
Monitoring: baseline and daily ECG; maintain K+ >4.0 mEq/L, Mg2+ >2.0 mg/dL

C. Gastrointestinal Effects

Opioid-induced ileus:

Pathophysiology: mu-receptor–mediated decreased peristalsis
Detection: abdominal exam, bowel sounds, stool chart
Mitigation: multimodal analgesia, scheduled bowel regimens, minimize continuous infusions

D. Neuromuscular Blocker Toxicity

Prolonged blockade and ICU-acquired weakness
Monitoring: train-of-four peripheral nerve stimulator aiming for 1–2 twitches of 4
Prevention: use cisatracurium in organ dysfunction; ensure deep sedation and eye care; daily interruption if feasible

3. Pharmacotherapy Considerations

Selection and dosing of sedatives, analgesics, antipsychotics, and NMBAs should account for mechanism, PK/PD, organ function, and monitoring requirements.

A. Sedation Agents

Common Sedation Agents in ICU
Agent	Mechanism	Dose	Onset/Offset	Key AEs	Organ Considerations
Propofol	GABA-A agonist	5–50 mcg/kg/min infusion; adjust by 5–10 mcg/kg/min q5–10 min	<1 min / <10 min	Hypotension, hypertriglyceridemia, PRIS	Avoid if unstable hemodynamics; monitor TGs every 48–72 hr
Dexmedetomidine	α2-agonist	0.2–1.5 mcg/kg/hr infusion; avoid loading dose in at-risk patients	10–20 min / 1–2 hr	Bradycardia, hypotension	Reduce dose in hepatic impairment
Midazolam	GABA-A agonist	0.02–0.1 mg/kg/hr infusion; boluses 1–2 mg	1–5 min / 1–6 hr	Accumulation, delirium, prolonged sedation	Avoid high cumulative doses; adjust in renal/hepatic failure

Key Pearl: Sedative Choice

Favor nonbenzodiazepine sedatives for shorter recovery times and lower delirium risk.

B. Analgesics

Fentanyl:

Metabolism: hepatic to inactive metabolites
Dose: 25–200 mcg/hr infusion; titrate to pain scores
Adjustments: minimal change in renal failure; monitor for chest wall rigidity with high-dose boluses

Hydromorphone:

Metabolism: hepatic to hydromorphone-3-glucuronide (neurotoxic in renal failure)
Dose: 0.5–5 mg/hr infusion; boluses 0.2–0.5 mg
Adjustments: reduce dose >50% in CrCl <30 mL/min

Adjuncts:

Ketamine infusion (0.2–0.5 mg/kg/hr), scheduled acetaminophen.

C. Sedatives/Antipsychotics with QT Risk

Use lowest effective dose of haloperidol or ziprasidone for agitation.
Alternative agents: quetiapine, olanzapine with lower QT effects.
Implement ECG monitoring protocol when QTc >450 ms.

D. Neuromuscular Blockers

Cisatracurium: Hofmann elimination; dose 0.03 mg/kg bolus then 1–3 mcg/kg/min infusion.
Rocuronium/Vecuronium: hepatic/renal clearance; dose-reduce in organ dysfunction.
Protocol: titrate to TOF 1–2/4; ensure deep sedation, analgesia, and corneal protection.

4. Dose Adjustment for Organ Dysfunction and Critical Illness

Renal and hepatic impairment and critical illness–induced PK/PD changes necessitate proactive dose modifications and monitoring.

A. Renal Impairment

Accumulation: midazolam, hydromorphone (active metabolites), aminosteroid NMBAs
Strategy: reduce infusion rates by 25–50%; extend dosing intervals; consult dialysis clearance data

B. Hepatic Impairment

Reduced clearance: propofol, dexmedetomidine, benzodiazepines
Strategy: lower starting doses by 25–50%; monitor for oversedation and prolonged effect

C. Critical Illness PK/PD Changes

Increased Vd: capillary leak, fluid resuscitation
Augmented renal clearance: subtherapeutic dosing risk for hydrophilic drugs
Hypoalbuminemia: increased free fraction of protein-bound drugs
Tools: use sedation/analgesia scales for titration; consider drug-level monitoring when available

5. Transition of Care and Liberation Strategies

Structured medication reconciliation, de-prescribing, and IV-to-enteral conversion protocols streamline extubation and support post-ICU recovery.

A. Medication Reconciliation

Perform within 24 hr of extubation planning.
Identify withheld chronic meds vs discontinued therapies.
Prioritize high-risk drugs (beta-blockers, antiepileptics, psychiatric agents).

B. De-prescribing Protocols

Incorporate daily sedation interruption and spontaneous awakening trials.
Weaning schedules: reduce sedative infusion by 20% every 4–6 hr as tolerated.

C. IV to Enteral Conversion

Determine enteral equivalents: e.g., oral midazolam 7.5 mg = IV 2 mg bolus.

Editor’s Note: Insufficient source material for detailed enteral conversion. A complete section would include drug-specific bioavailability, tube-compatibility guidelines, and crushing/formulation protocols.

D. Reinitiation of Chronic Medications

Resume cardiovascular, endocrine, and psychiatric therapies once enteral feeding established.
Monitor for rebound hypertension, withdrawal symptoms, glycemic control.

E. Multidisciplinary Handoffs

Use standardized checklist documenting sedation status, pain control, NMBA use, bowel regimen, chronic meds.
Engage pharmacists in ICU-to-floor handoff rounds.

6. Case-Based Applications and Decision Algorithms

Algorithms and checklists facilitate consistent management of common scenarios during liberation.

Figure 1: Management of Hypotensive Patient on Propofol

A. Hypotensive Patient on Propofol

1. Initial Assessment: Assess volume status and identify reversible causes of hypotension (e.g., hemorrhage, sepsis, new cardiac event).

↓

2. Sedation Adjustment: Decrease propofol infusion by 5–10 mcg/kg/min.
Consider: If hypotension is severe or persistent, switch to an alternative sedative with less hemodynamic impact (e.g., dexmedetomidine, if bradycardia is not a concern).

↓

3. Fluid Optimization: If hypovolemic, administer fluid bolus as appropriate.

↓

4. Vasopressor Support: If hypotension persists despite sedation adjustment and fluid optimization, consider initiating or titrating vasopressors.

Figure 2: Dose Titration in Acute Kidney Injury (AKI)

B. Dose Titration in Acute Kidney Injury

1. Identify At-Risk Medications: List all current medications that are primarily renally cleared or have active metabolites accumulating in AKI (e.g., midazolam, hydromorphone, morphine, aminosteroid NMBAs like rocuronium/vecuronium).

↓

2. Dose Reduction/Interval Extension:

Reduce infusion rates of affected drugs by 25–50% based on AKI severity (e.g., CrCl estimate).
Extend dosing intervals for intermittent medications.

↓

3. Enhanced Monitoring:

Closely monitor sedation depth (e.g., RASS scores).
Monitor neuromuscular function (e.g., TOF for NMBAs, clinical signs of weakness).
Watch for signs of drug accumulation/toxicity (e.g., prolonged sedation, myoclonus with opioids).

↓

4. Adjust per Dialysis: If patient is on renal replacement therapy, consult specific drug clearance data for the modality used and adjust dosing schedule accordingly (e.g., redose after intermittent hemodialysis if significantly cleared).

Figure 3: Extubation Readiness Pharmacotherapy Checklist

C. Extubation Readiness Checklist

Sedation light (e.g., RASS –2 to 0) and weaned significantly OR successfully transitioned to an appropriate enteral/oral regimen.
Neuromuscular blockade (NMBA) discontinued for an adequate period; Train-of-Four (TOF) 4/4 confirmed if recently used.
Adequate pain control on current analgesic regimen (consider transition to PRN or oral options).
Bowel regimen initiated and patient has evidence of bowel function (if on opioids).
Chronic home medications reviewed, reconciled, and reinitiated as appropriate (especially cardiovascular, antiepileptic, psychiatric medications).
Plan for managing potential agitation or delirium post-extubation in place.
Multidisciplinary team (physician, nurse, respiratory therapist, pharmacist) agrees on readiness from a pharmacotherapy perspective.

7. Key Pearls and Summary

Top Safety Monitoring Tips:

Continuous hemodynamic monitoring during propofol and dexmedetomidine infusions.
Baseline and serial ECGs for QT-prolonging agents.
Daily bowel assessments in opioid-treated patients.
TOF monitoring for all patients on NMBAs.
Vigilance for signs of drug accumulation in organ dysfunction.

Essential Dose-Adjustment Rules:

Reduce benzodiazepines and aminosteroid NMBAs in renal/hepatic impairment.
Lower dexmedetomidine dose in liver dysfunction.
Prefer cisatracurium for NM blockade in organ failure.

Extubation Checklist for Pharmacists:

Medication reconciliation and de-prescribing initiated.
Sedatives/analgesics weaned or converted to enteral.
NMBA reversed and monitored (if applicable).
Chronic therapies resumed appropriately.
ICU-to-floor handoff with pharmacist involvement.

References

Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult ICU Patients. Crit Care Med. 2018;46(9):e825–e873.
Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in mechanically ventilated patients. N Engl J Med. 2000;342(20):1471–1477.
Ronan KP, Gallagher TJ, George B, Hamby B. Comparison of propofol and midazolam for sedation in ICU patients. Crit Care Med. 1995;23:286–293.

2025 PACUPrep BCCCP Preparatory Course

Pulmonary

Participants 432